OBJECTIVE: To investigate longitudinal change in the medical decision-making capacity (MDC) of patients with amnestic mild cognitive impairment (MCI) under different consent standards. METHODS: Eighty-eight healthy older controls and 116 patients with MCI were administered the Capacity to Consent to Treatment Instrument at baseline and at 1 to 3 (mean = 1.7) annual follow-up visits thereafter. Covariate-adjusted random coefficient regressions were used to examine differences in MDC trajectories across MCI and control participants, as well as to investigate the impact of conversion to Alzheimer disease on MCI patients' MDC trajectories. RESULTS: At baseline, MCI patients performed significantly below controls only on the three clinically relevant standards of appreciation, reasoning, and understanding. Compared with controls, MCI patients experienced significant declines over time on understanding but not on any other consent standard. Conversion affected both the elevation (a decrease in performance) and slope (acceleration in subsequent rate of decline) of MCI patients' MDC trajectories on understanding. A trend emerged for conversion to be associated with a performance decrease on reasoning in the MCI group. CONCLUSIONS: Medical decision-making capacity (MDC) decline in mild cognitive impairment (MCI) is a relatively slow but detectable process. Over a 3-year period, patients with amnestic MCI show progressive decline in the ability to understand consent information. This decline accelerates after conversion to Alzheimer disease (AD), reflecting increasing vulnerability to decisional impairment. Clinicians and researchers working with MCI patients should give particular attention to the informed consent process when conversion to AD is suspected or confirmed.
OBJECTIVE: To investigate longitudinal change in the medical decision-making capacity (MDC) of patients with amnestic mild cognitive impairment (MCI) under different consent standards. METHODS: Eighty-eight healthy older controls and 116 patients with MCI were administered the Capacity to Consent to Treatment Instrument at baseline and at 1 to 3 (mean = 1.7) annual follow-up visits thereafter. Covariate-adjusted random coefficient regressions were used to examine differences in MDC trajectories across MCI and control participants, as well as to investigate the impact of conversion to Alzheimer disease on MCI patients' MDC trajectories. RESULTS: At baseline, MCI patients performed significantly below controls only on the three clinically relevant standards of appreciation, reasoning, and understanding. Compared with controls, MCI patients experienced significant declines over time on understanding but not on any other consent standard. Conversion affected both the elevation (a decrease in performance) and slope (acceleration in subsequent rate of decline) of MCI patients' MDC trajectories on understanding. A trend emerged for conversion to be associated with a performance decrease on reasoning in the MCI group. CONCLUSIONS: Medical decision-making capacity (MDC) decline in mild cognitive impairment (MCI) is a relatively slow but detectable process. Over a 3-year period, patients with amnestic MCI show progressive decline in the ability to understand consent information. This decline accelerates after conversion to Alzheimer disease (AD), reflecting increasing vulnerability to decisional impairment. Clinicians and researchers working with MCI patients should give particular attention to the informed consent process when conversion to AD is suspected or confirmed.
Authors: Serge Gauthier; Barry Reisberg; Michael Zaudig; Ronald C Petersen; Karen Ritchie; Karl Broich; Sylvie Belleville; Henry Brodaty; David Bennett; Howard Chertkow; Jeffrey L Cummings; Mony de Leon; Howard Feldman; Mary Ganguli; Harald Hampel; Philip Scheltens; Mary C Tierney; Peter Whitehouse; Bengt Winblad Journal: Lancet Date: 2006-04-15 Impact factor: 79.321
Authors: Dinesh Mittal; Barton W Palmer; Laura B Dunn; Reid Landes; Courtney Ghormley; Cornelia Beck; Shah Golshan; Dean Blevins; Dilip V Jeste Journal: Am J Geriatr Psychiatry Date: 2007-02 Impact factor: 4.105
Authors: K Pérès; V Chrysostome; C Fabrigoule; J M Orgogozo; J F Dartigues; P Barberger-Gateau Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: O Okonkwo; H R Griffith; K Belue; S Lanza; E Y Zamrini; L E Harrell; J C Brockington; D Clark; R Raman; D C Marson Journal: Neurology Date: 2007-10-09 Impact factor: 9.910
Authors: Virginia G Wadley; Michael Crowe; Michael Marsiske; Sarah E Cook; Frederick W Unverzagt; Adrienne L Rosenberg; Daniel Rexroth Journal: J Am Geriatr Soc Date: 2007-08 Impact factor: 5.562
Authors: Cynthia Z Burton; Elizabeth W Twamley; Lana C Lee; Barton W Palmer; Dilip V Jeste; Laura B Dunn; Scott A Irwin Journal: Am J Geriatr Psychiatry Date: 2012-04 Impact factor: 4.105
Authors: H Randall Griffith; Ozioma C Okonkwo; Jan A den Hollander; Katherine Belue; Jacqueline Copeland; Lindy E Harrell; John C Brockington; David G Clark; Daniel C Marson Journal: Neuropsychol Dev Cogn B Aging Neuropsychol Cogn Date: 2010-04-06
Authors: Kristen L Triebel; Ozioma C Okonkwo; Roy Martin; Henry Randall Griffith; Martha Crowther; Daniel C Marson Journal: Alzheimer Dis Assoc Disord Date: 2010 Oct-Dec Impact factor: 2.703
Authors: Xin Gao; Holly G Prigerson; Eli L Diamond; Baohui Zhang; Alexi A Wright; Fremonta Meyer; Paul K Maciejewski Journal: J Pain Symptom Manage Date: 2012-07-28 Impact factor: 3.612
Authors: Daniel C Marson; Roy C Martin; Virginia Wadley; H Randall Griffith; Scott Snyder; Patricia S Goode; F Cleveland Kinney; Anthony P Nicholas; Terri Steele; Britt Anderson; Edward Zamrini; Rema Raman; Alfred Bartolucci; Lindy E Harrell Journal: J Am Geriatr Soc Date: 2009-04-21 Impact factor: 5.562